Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Facing COVID Surge, China Revises Course To Support Imported mRNA Vaccines

Major Policy Shift Expected

Executive Summary

Latest announcement from Shanghai government set to open foreign mRNA jabs to the arms of Chinese people, after months of stalling approvals.

You may also be interested in...



Could New Data Herald China Approval For Comirnaty?

Long-term safety results from the mRNA COVID-19 vaccine’s Phase II trial in a Chinese population could pave the way for its approval in China, investigators say.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: time runs out to scale the next patent cliff; Novartis searches for new blockbuster; Boehringer Ingelheim’s R&D spending pays off; Shanghai eyes mRNA vaccines as COVID cases rise; and the global pharma R&D pipeline hits new heights.

Shanghai Lockdown Puts New Spotlight On China COVID Policies

The largest-ever COVID-related lockdown in Shanghai is offering an indication of the effectiveness of current Chinese policies around current controls and domestic vaccines, as well as prompting consideration of future directions for control and treatment measures as the pandemic moves to the endemic phase.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel